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Abstract
About 2% of all paragangliomas are located in the chest, and a few have been described to be found in the heart.
Primary cardiac paragangliomas are extremely uncommon tumors and surgical experience with this neoplasm is
limited. Treatment strategies described in the literature have included simple excision, excision with reconstruction,
autotransplantation after excision of the tumor and even orthotopic cardiac transplantation, depending on the
extent of disease. A primary retrocardiac paraganglioma catecholamine-productive was identified in an
asymptomatic 49–year old female associated to familial pheochromocytoma-paraganglioma syndrome caused by
germline mutation of the gen which codifies for the subunit B of succinate dehydrogenase enzyme (SDHB). The
neoplasm was surgically excised from the posterior surface of the left atrium via median sternotomy using
cardiopulmonary bypass. Direct ligation of feeding vessels of the tumor along with left atrial reinforcement using a
pericardial patch was performed. The post-operative course was uneventful, with normalization of catecholamine
secretion and no recurrence at three-month follow-up. We review the current literature about this exceptional
cardiac tumor, pathophysiological conditions and options for surgical management.
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Background
Pheochromocytomas are catecholamine-producing neu-
roendocrine tumors arise from the chromaffin cells of the
embryonic neural crest. It is estimated that the annual
incidence is approximately 0.8 per 100.000 persons and
they occur most often in the fourth to fifth decade [1].
They are highly vascularised but usually benign tumors,
although about 10% of pheochromocytomas are found to
be malignant at the time of the primary tumor is
discovered.
About 85–90% of them develop in the abdomen (they
are usually found within one or both adrenal glands) and
only 10% originates from extra-adrenal sites. Extra-adrenal
pheochromocytomas (often described as extra-adrenal
paragangliomas) originate in the ganglia of the sympathetic
nervous system and most are located within the abdomen
(celiac, superior mesenteric, inferior mesenteric ganglia and
organ of Zuckerkandl), head and neck (3%, including
carotid and vagal bodies), urinary bladder (1%) and media-
stinal compartments (less than 1%) [2].
Thoracic paragangliomas are the most uncommon loca-
tion and they can be divided into two groups: those located
in the anterior mediastinum (arise from parasympathetic
paraganglia) and located in the posterior mediastinum
(sympathetic chain). Primary cardiac pheochromocytomas
(paragangliomas) are extremely rare, occurring in only
0.001%–0.003%, with female predominance [3].
In general terms, the clinical manifestations of these
tumors are varied, not particularly specific and it depends
on the secretion of excessive amounts of catecholamines,
such as noradrenaline (norepinephrine) and adrenaline
(epinephrine). Although these tumors may be a cause of
hypertension, they are the underlying cause of only about
0.01% of cases of high blood pressure.
About 75% of pheochromocytomas are sporadic and the
remaining 25% are hereditary. Mutations of the genes
which codify for the subunits D, A, C y B of succinate
dehydrogenase enzyme (SDHD, SDHA, SDHC and
SDHB) involved in the Krebs cycle can lead to tumor-
ogenesis in chromaffin cells and they have been
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identified as causing familial adrenal pheochromocy-
toma and extra-adrenal paraganglioma; moreover, these
tumors may also occur in the multiple endocrine neoplasia
(MEN) syndrome type 2A and 2B, von Hippel-Lindau dis-
ease or von Recklinghausen’s neurofibromatosis [4].
The diagnosis of these tumors can be established by
measuring catecholamines and metanephrines in plasma or
24-hour urine along with imaging techniques such as com-
puted tomography (CT), magnetic resonance imaging,
iodine-123-marked metaiodobenzylguanidine (MIBG) scan
and positron emission tomography (PET) scan [5].
Treatment of pheochromocytomas involves blocking
the effect of catecholamines with an alpha adrenergic
blocker and after, it then becomes safe to surgically
remove the tumor. Although surgical resection is the
treatment of first choice in most part of cases, extra-
adrenal localizations (such as those paragangliomas origi-
nated in cardiac structures) involve an uncommon and
complex surgical approach for a complete removal.
We describe a case of surgical excision of a primary
functioning retrocardiac paraganglioma associated with
hereditary syndrome and we review the relevant literature
about the peculiar features and surgical strategies for
removal of this cardiac neoplasm.
Case presentation
We report a case of an asymptomatic 49-year old
Caucasian female, with hereditary type 4 pheochromocy-
toma-paraganglioma syndrome caused by germline
mutation (alanine–43–proline) of the gen which codifies
for the subunit B of succinate dehydrogenase enzyme
(SDHB) of the mitochondrial complex II. She had a
Figure 1 A. Computed tomography imaging reconstruction of the heart. The tumor is showed. The collateral vessel (white arrow) from the
circumflex artery (CxA) is observed. B. 18-F DOPA PET showed a 16 × 25 × 36 mm extracardiac mass protruding within the LA. Presence of
metabolic activity was detected. C. Computed tomography (axial view) showed the presence of the large mass (red arrow). D. Coronary
angiography. The coronary blood supply of the superior aspect of the paraganglioma (T) emerged from a large collateral vessel (white arrow)
from the right coronary artery (RCA). E. Coronary angiography. Proximal and distal collaterals from CxA were the feeding vessels (white arrow) of
the inferior aspect of the tumor (T).
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family history of extra-adrenal paraganglioma: genetic
testing had revealed the gen SDHB mutation for eight
first- and second-degree relatives and carotid body para-
ganglioma had been resected in three of them. Urinary
and plasma levels of catecholamines (noradrenaline and
adrenaline) and their metabolites (normetanephrine)
were elevated and computed tomography of the abdo-
men ruled out adrenal gland involvement.
Total body MIBG scintigraphy scan and 18F-dihydroxy-
phenyl-alanine (18F-DOPA) PET scan showed a primary
retrocardiac mass with metabolic activity. Metastasic
disease was not found and no other intrathoracic masses
were identified. Transesophageal echocardiography (TOE)
and TC imaging of the heart showed the large mass
(40 × 20 mm), extrinsic to the heart, on the posterior wall
of the left atrium (LA) (Figure 1A-C). Coronary angio-
graphy and aortography were performed: the tumor
received dual blood supply from both right and left coro-
nary arteries (Figure 1D-E). No feeding vessels from the
aortic arch or thoracic descending aorta (bronchial
arteries) were demonstrated.
Alpha-adrenergic pharmacologic therapy (phenoxy-
benzamine) was instituted before operation for the
catecholamine-secreting tumor. She underwent surgical
removal of the retrocardiac tumor via median sterno-
tomy. As part of our initial surgical planning, cardio-
pulmonary bypass (CPB) was started through right
femoral artery and venous cannulation (right femoral
vein and superior vein cava) (Figure 2A-B) because of
surgical excision could be technically difficult by the
position of the tumor. Moderate hypothermia (31°C)
was instaured and the heart was arrested using ante-
grade cold blood cardioplegia. The tumor was found as
an “imprisoned” mass between the four pulmonary
veins: it extended from the right to the left superior
pulmonary vein, and caudally, between the inferior
pulmonary veins. The lesion was confined to this retro-
cardiac area as a firm adherent mass, although it was
not adherent to adjacent structures.
Direct ligation of feeding vessels was performed for
control of bleeding: the collaterals vessels from the right
coronary artery (RCA) and circumflex artery (CxA) were
ligated (Figure 2C-D). TOE was used to confirm success-
ful interruption of blood flow to the tumor and no elec-
trical changes were noted.
Following excision of the superior pericardial reflection
(Figure 3A), the left posterior atrial wall was exposed and
the superior aspect of the tumor was excised. Then, the
heart was suspended for removal of the inferior aspect of
the tumor. There was no a plane of cleavage between the
LA and the tumor, and atrial myocardium was also
removed (Figure 3B-C). The division of great vessels and
LA was not necessary to access the tumor and it was com-
pletely excised en bloc (Figure 3D). Coronary sinus,
Figure 2 A. Peripheral perfusion through right femoral artery and vein. B. Superior vein cavae (SVC) drainage through Pacifico cannula.
C. The large collateral vessel from the RCA was dissected and ligated. RA: Right atrium. Ao: Aorta. D. The two collateral vessels from CxA
(white arrow) were also ligated for an optimal control of bleeding during the excision of the tumor. CS: Coronary sinus. LPVs: Left pulmonary veins.
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Figure 3 A. Surgeon’s view. Superior aspect of the tumor (black arrow) is showed. Neovascularization of the smooth surface is observed.
B. Endocardium of the LA was exposed (black arrow) during surgical excision (suspended heart). C. Surgeon’s view. Dissection of the superior
aspect of the tumor (T). D. Paraganglioma (T) after totally excision from the LA. IVC: Inferior vein cava. LIPV: Left inferior vein cava.
Figure 4 A. LA after removal of the tumor. The operative photograph shows the distal collateral vessel (white arrow) from CxA (after ligation).
Endocardium of the LA remained in situ. LAA: Left atrial appendage. OS: Oblique sinus. B. Bovine pericardial patch (black arrow) was used for left
atrial reconstruction. The suture was started from the left atrial roof. C-D. Pericardial patch was placed on the posterior wall of the LA using a
polypropylene running suture.
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pulmonary veins and left atrial appendage were not
involved. Adequate disease-free margins were achieved
and the denuded LA was reconstructed using a bovine
pericardial patch (Figures 4A-D and 5A) and it was rein-
forced with surgical sealant.
CPB time was 143 minutes and aortic cross-clamping
time was 105 minutes. Intraoperative TOE revealed a
complete excision of the tumor and no perioperative hyper-
tensive crisis on palpation of the tumor were demonstrated.
The patient was then weaned from bypass successfully.
Histological examination confirmed the paraganglioma
and malignant changes were not found (Figure 5B-C).
Chromogranin and synaptophysin were positive at immu-
nohistochemistry, and sustentacular cells were positive for
S–100 protein staining (Figure 5D).
The post-operative course was uneventful, no bleeding
was detected, sinus rhythm was maintained and antihy-
pertensive therapy was not necessary. She was discharged
at 8th post-operative day and short-term anticoagulation
was started for prevention of LA thrombus formation
due to transient endothelial dysfunction. At 3–month
follow-up, she remains asymptomatic and biochemical
evaluations have confirmed the normalization of levels of
catecholamines.
Discussion
Cardiac paraganglionic tumors are rare neoplasms
derived from the neural crest in the mediastinum, asso-
ciated with the autonomic nervous system, which
account for 0.3% of all mediastinal neoplasms and less
than 1% of all primary cardiac tumors [6]. They arise
from either the branchiomeric paraganglia (coronary or
aortopulmonary) or the visceral-autonomic paraganglia
(atrium or interatrial septum) and less than 50% are
functional; the majority of functional tumors are intra-
adrenal pheochromocytomas, being uncommon at the
heart.
Edwin Besterman (St. Mary’s Hospital, London) was the
first author to report a successful resection on CPB of a
cardiac pheochromocytoma in the LA in 1974 [7] and to
date, fewer than 50 cases have been reported in the medical
literature [8,9] and they are typically located adjacent to or
involving the LA [10], although these tumors have been
described to be found in the interatrial septum [11], right
atrium, inferior vein cava [12], root of the great arteries [13]
or proximal part of coronary arteries [14], possibly
explained by close proximity of paraganglionic cell nest.
Clinical presentation depends on the functional status
of the paraganglioma and the location at the heart:
Figure 5 A. Posterior LA after pericardial replacement. B. Macroscopic examination (6 × 3 × 1.5 cm fragment). A well-demarcated
homogeneous, smooth surfaced and highly vascularized tumor (2.8 × 2.5 × 1.5 cm) was found, with clear surgical margins. C. Histological
examination. Haematoxylin and eosin staining (H & E, 40x magnification) showing the “zellballen” packeting of cells, without atypia, surrounded
by capillary network (blue arrow). D. Immunohistochemical analysis (40x magnification) revealed the specific neuroendocrine markers
(chromogranin and synaptophysin, C & S). S-100 protein staining technique (100x magnification) revealed the sustentacular cell network
(black arrow).
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paroxysmal hypertension due to secretion of catechola-
mines, chest pain [15], symptoms secondary to pericar-
dial involvement or invasion of the conduction system
[16] or inespecified symptoms such as fever or malaise.
In cases of extension to valves, other primary cardiac
tumors such as mixoma or angiosarcoma must be
excluded. More unusual presentations have been
reported such as acute myocardial infarction and stroke
[17], although in some cases, the tumor can be an inci-
dental finding. A curious feature of the tumor in our pa-
tient was the absence of symptoms despite to be a
functioning paraganglioma.
In a short number of patients, cardiac paragangliomas
can be associated to hereditary syndromes such as the
Carney triad (pulmonary chondromas, gastric stromal
tumors and extra-adrenal paragangliomas) [18] or fami-
lial pheochromocytoma-paraganglioma syndromes. In
the reported case, the familial pheochromocytoma-
paraganglioma syndrome type 4 had been previously
detected. These syndromes involve a group of rare auto-
somal dominant disorders affecting sympathetic and para-
sympathetic paraganglia, caused by germline mutations of
the genes SDHB, SDHC and SDHD, although some of
these mutations can also be detected for patients with
apparently sporadic pheochromocytomas [19].
Most cardiac paragangliomas are benign, but local
invasion can occur and metastases have been reported
in isolated cases [20,21]. Location in the heart is not
particularly associated with familial syndromes, although
malignant predisposition is increased with the SDHB
mutation [22]. Because of this reason, long-term follow-
up is mandatory in our patient due to the implications
of this hereditary disorder. However, malignant primary
paragangliomas of the heart are exceptional and to date,
there are no reported cases associated to this mutation.
The preoperative goals for this type of tumors are to
normalize hemodynamic variables such as blood pres-
sure and avoid surges in catecholamine release with
tumor manipulation during surgery. Nevertheless, pre-
operative alpha-1-adrenoceptor antagonist seems to have
no benefit in maintaining intraoperative hemodynamic
stability in patients with normotensive adrenal pheo-
chromocytoma [23]. Although our patient showed
normal preoperative levels of blood pressure despite to
be a catecholamine-secreting tumor and it is important
to bear in mind these recent considerations, no evidence
about normotensive cardiac paragangliomas has been
reported and we consider the alpha-blockade prepa-
ration for this isolated case.
Less than 40 cases about surgical excision of a cardiac
paraganglioma have been described in adults [24] and
the surgical treatment is similar to that of all other
cardiac tumors; the approach can be either a median
sternotomy or posterolateral thoracotomy depending on
the location in the mediastium, but some technical
details must be made.
Because they are highly vascular, some groups advocate
the embolization before surgery to reduce perioperative
bleeding [25] when surgical excision of a bulky tumor at a
difficult location is planned. Although preoperative
embolization has been widely described in the treatment
of paragangliomas of the neck and carotid body, it has
been reported in a few cases of mediastinal paraganglio-
mas. For these situations, superselective angiography and
subsequent embolization must be carried out 1 to 6 days
preoperatively for a complete disappearance of the tumor
blush and a safe surgical excision.
Nevertheless, in our patient, for prevention of a ca-
tastrophic haemorrhage during the time of the operation, a
direct ligation of feeding vessels of the tumor was
performed. To date, isolated cases of direct ligation at
surgery have been described [26] and no comparative
results between the two options are available.
As these tumors are of locally invasive nature and they
have a less well-defined capsule than adrenal pheochro-
mocytomas, a complete resection can be technically dif-
ficult by the position of the tumor and should be
performed on CPB and cardioplegic arrest in the most
part of cases in order to achieve disease-free excision
margins. When the interatrial septum is involved, the
anterior aspect of the septum must be preserved to avoid
heart block; in other situations, the tumor invades
surrounding vascular structures and resection may be
extremely difficult. For selected patients, extensive cardiac
reconstructive surgery may therefore be required, with its
associated risks. Our patient underwent a successful
complete resection of the “caged” tumor between the
pulmonary veins along with reconstruction of the resected
site and no complications were detected after surgery.
Reconstruction of the LA using either autologous or
bovine pericardial patch has been previously described
and, when a portion of the pulmonary veins is also infil-
trated and excised, it must be repaired and reconstructed
with the patch [27], although these cases are at risk for
development of pulmonary stenosis at follow-up. Recon-
struction of right ventricular outflow tract and pulmonary
valve has also been reported when local invasion is
detected [28] following the removal of the tumor en bloc
with adjacent structures such as thymus, pericardium, part
of pulmonary trunk and anterior leaflet of pulmonary
valve.
Although surgical resection and reconstruction is the
gold standard treatment for these tumors, this approach
can be impossible due to extensive involvement of the
great vessels or other structures of the heart. When total
surgical resection is extremely difficult, cardiac autotrans-
plantation has been described and, in selected cases, when
a complete removal is not possible, orthotopic cardiac
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transplantation is a feasible technique in those paragan-
gliomas that have direct coronary artery involvement,
extend into the left ventricle or invade the atrioventricular
groove [29]. In general terms, although operative mortality
and overall survival seems favorable in series of patients
with primary cardiac tumors and benefits of this tech-
nique include improved accessibility and ability to per-
form a complete tumor resection, there are few reports of
transplantation for excision of cardiac paragangliomas in
the literature and late results are unknown [29].
In the only reported case series including 14 patients
over the last 30 years, at Mayo Clinic [30], Brown et al.
have reported a safe resection of these tumors often
under CPB with modest surgical risk, with one intra-
operative death due to massive bleeding (in the only
tumor of this serie involving the LA) and a total number
of 10 patients were alive at follow-up (median follow-up:
2.3 years). The SDHB mutation was detected in two
patients of the serie.
When a complete removal of the tumor is achieved,
long-term prognosis seems to be excellent and survival of
up to 14 years has been reported in a patient with excised
mediastinal paraganglioma [31]. To date, surveillance can
be done by following serum catecholamine levels, repea-
ting CT scans and/or TOE, and most recently MIBG scan
and PET imaging. Recent data support the superiority of
18F-DOPA PET-CT over 123–I–MIBG scintigraphy to
assess disease extension in patients with recurrent para-
ganglioma [32] and it might be the preferred test in this
patient follow-up because of the implications of the
hereditary syndrome. However, there is no consensus on
the treatment if the tumor does recur at follow-up.
Our case is relevant in that there were no classic signs
of catecholamine excess despite to be a functioning
tumor and it illustrates successful management of a
benign left atrial primary paraganglioma associated with
SDHB mutation, including direct ligation of feeding
vessels of the tumor, complete excision and subsequent
reinforcement of the LA, without evidence of recurrence
at short-term follow-up.
Conclusions
– Primary cardiac paragangliomas are exceptional
tumors and surgical resection is the gold standard
treatment.
– Control of feeding vessels, complete resection of the
tumor and reconstruction of the resected sites are
the goals for surgical management.
– Although treatment strategies can be varied
according to the extent of the disease, in general
terms, cardiac paragangliomas can be safely resected
using well-established surgical techniques with
appropriate surgical planning.
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